Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer [Gastrointestinal Cancer]

Conclusion
The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib.

Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Catenacci, Junttila, Karrison, Bahary, Horiba, Nattam, Marsh, Wallace, Kozloff, Rajdev, Cohen, Wade, Sleckman, Lenz, Stiff, Kumar, Xu, Henderson, Takebe, Salgia, Wang, Stadler, de Sauvage, Kindler Tags: Clinical Trials, Chemotherapy, Translational Oncology, Gastrointestinal Gastrointestinal Cancer Source Type: research